Insmed (INSM) Intangibles (2010 - 2026)

Insmed (INSM) posted quarterly Intangibles of $95.6 million for Q1 2026, down 2.13% quarter-over-quarter from $97.7 million in Q4 2025.

Insmed (INSM) Intangibles (2010 - 2026) Analysis & Trends

Insmed's Intangibles history runs 17 years deep, the most recent figure standing at $95.6 million for Q1 2026.

In Q1 2026, Intangibles changed N/A year-over-year to $95.6 million; the TTM figure through Mar 2026 stood at $95.6 million (changed N/A YoY), while the FY2025 annual figure was $97.7 million, up 66.49% from the prior year.
Intangibles for Q1 2026 stood at $95.6 million, down from $97.7 million in the prior quarter.
The five-year high for Intangibles was $97.7 million in Q4 2025, with the low at $56.1 million in Q2 2025.
The 5-year median for Intangibles is $69.4 million (2022), against an average of $72.4 million.
The sharpest annual moves came in 2024 and 2025: Intangibles declined 7.93% in 2024, then jumped 66.49% in 2025.
Insmed's Intangibles stood at $68.8 million in 2022, then decreased by 7.35% to $63.7 million in 2023, then dropped by 7.93% to $58.7 million in 2024, then jumped by 66.49% to $97.7 million in 2025, then declined by 2.13% to $95.6 million in 2026.
Business Quant data shows INSM's Intangibles at $95.6 million in Q1 2026, $97.7 million in Q4 2025, and $84.6 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	266.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	63.28 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	60.96 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	93.49 Mn
10	Roivant Sciences	26.16 Bn	26.85 Bn	1.16 Mn	-

Download Data